Medical aid group to host 3 Ebola clinical trials in West Africa

Doctors Without Borders will begin clinical trials next month in three Ebola treatment centres using experimental drugs, other trials also slated to begin

GENEVA – Accelerated clinical trials will be launched in West Africa to speed the search for a treatment for the deadly Ebola virus, Doctors Without Borders announced Thursday.

The international humanitarian group said it will host clinical trials starting next month in three Ebola treatment centres using experimental drugs that haven’t been through the usual lengthy process of study with animals and healthy people.

Separate trials will be led by three different research partners and involve the U.N. World Health Organization and health officials in affected countries.

“If we’re going to find a treatment, we have to do it now – which is why we have to accelerate these trials,” said Peter Horby, the chief investigator for the trial led by Oxford University.

Oxford’s trial will test the antiviral drug brincidofovir in Liberia.

France’s National Institute of Health and Medical Research will conduct a trial using the antiviral drug favipiravir in Gueckedou, Guinea, and the Antwerp Institute of Tropical Medicine will test convalescent whole blood and plasma therapy in Guinea.

Results from some of the trials are expected by February or March.

The largest-ever outbreak of Ebola has raged for than eight months, killing more than 5,000 people and infecting more than 14,000 in West Africa.

The United Nations has appointed an Ebola chief and various governments have set up clinics. But medical teams are stretched thin and the U.N. health agency WHO says there are not enough foreign medical workers.

There are no established drugs for Ebola. Human testing of a handful of experimental drugs for Ebola has begun on several continents. The current outbreak kills between 50 and 80 per cent of those infected in West Africa, according to Doctors Without Borders.

Looking for more?

Get the Best of Maclean's sent straight to your inbox. Sign up for news, commentary and analysis.